BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17000997)

  • 1. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Goodin DS
    Neurology; 2006 Sep; 67(6):1104; author reply 1104-5. PubMed ID: 17000997
    [No Abstract]   [Full Text] [Related]  

  • 2. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
    Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nexus between lipids and multiple sclerosis?
    Zorzon M
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1181. PubMed ID: 23595948
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
    O'Connor P; Kinkel RP; Kremenchutzky M
    Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
    Weinstock-Guttman B; Zivadinov R; Horakova D; Havrdova E; Qu J; Shyh G; Lakota E; O'Connor K; Badgett D; Tamaño-Blanco M; Tyblova M; Hussein S; Bergsland N; Willis L; Krasensky J; Vaneckova M; Seidl Z; Ramanathan M
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1186-91. PubMed ID: 23595944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interferon beta-1a].
    Taéron C
    Rev Infirm; 2004 May; (101):39-40. PubMed ID: 15984751
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
    Almeida L; Neves M; Cardoso E; Melo A
    J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis.
    Duchini A
    Am J Gastroenterol; 2002 Mar; 97(3):767-8. PubMed ID: 11922585
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of interferon beta at the time of initial diagnosis of multiple sclerosis.
    Pender MP
    J Clin Neurosci; 2001 Jul; 8(4):381-2. PubMed ID: 11437589
    [No Abstract]   [Full Text] [Related]  

  • 11. [About the article: "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al].
    Labetouelle M
    J Fr Ophtalmol; 2001 Feb; 24(2):222. PubMed ID: 11332406
    [No Abstract]   [Full Text] [Related]  

  • 12. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
    [No Abstract]   [Full Text] [Related]  

  • 13. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon beta produces only small benefits in multiple sclerosis.
    McKee L
    BMJ; 1998 May; 316(7142):1410. PubMed ID: 9616008
    [No Abstract]   [Full Text] [Related]  

  • 15. 10 years of interferon beta-1b (Beta feron therapy.
    Kappos L; Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii1-iii2. PubMed ID: 16170493
    [No Abstract]   [Full Text] [Related]  

  • 16. Interferon beta in the treatment of multiple sclerosis--closing remarks.
    Kappos L
    Mult Scler; 1995; 1 Suppl 1():S64-6. PubMed ID: 9345403
    [No Abstract]   [Full Text] [Related]  

  • 17. ["The largest snapshot of multiple sclerosis". Interferons compared].
    MMW Fortschr Med; 2003 Jun; 145(24):55. PubMed ID: 12866307
    [No Abstract]   [Full Text] [Related]  

  • 18. Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon?
    Hodgkinson SJ
    J Clin Neurosci; 2001 Jul; 8(4):378-9. PubMed ID: 11437587
    [No Abstract]   [Full Text] [Related]  

  • 19. Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon? The case against.
    Macdonell R
    J Clin Neurosci; 2001 Jul; 8(4):379-81. PubMed ID: 11437588
    [No Abstract]   [Full Text] [Related]  

  • 20. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.